Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited... more
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare aggressive malignancy with poor outcomes. Although novel options like tagraxofusp, a CD123-directed cytotoxin, has emerged and is promising, treatment options are very limited in the relapsed and recurrent setting. We present a case of refractory BPDCN in a 62-year-old man who showed a complete bone marrow response to liposomal daunorubicin and cytarabine (vyxeos).
Research Interests:
Research Interests:
For more than two decades, hydroxyurea was the only therapeutic agent approved by the Food and Drug Administration (FDA) for sickle cell disease (SCD). Although curative allogeneic hematopoietic stem cell transplants (allo-HSCT) were also... more
For more than two decades, hydroxyurea was the only therapeutic agent approved by the Food and Drug Administration (FDA) for sickle cell disease (SCD). Although curative allogeneic hematopoietic stem cell transplants (allo-HSCT) were also available, only very few patients underwent the procedure due to lack of matched-related donors. However, therapeutic options for SCD patients increased dramatically in the last few years. Three new agents, l-glutamine, crizanlizumab, and voxelotor, were approved by the FDA for use in SCD patients. The number of SCD patients who underwent allo-HSCT also increased as a result of advances in the prevention of graft failure and graft-versus-host disease from using mismatched donor HSC. More recently gene therapy was made available on clinical trials. The increased treatment options for SCD have led to a sense of optimism and excitement among many physicians that these new approaches would alter the clinical course and disease burden. Although these newer agents do provide hope to SCD patients, the hyped-up responses need to be evaluated in the context of reality. In this review, we will discuss and compare these new agents and cell-based therapy, evaluate their clinical and economic impacts, and examine their roles in reducing the disease burden.
Research Interests:
496 ISSN: 2278 – 1323 All Rights Reserved © 2016 IJARCET Abstract— With the excessive use of internet cloud has received much of the attention. With the help of cloud data can be easily stored on cloud and can be accessed on demand.... more
496 ISSN: 2278 – 1323 All Rights Reserved © 2016 IJARCET Abstract— With the excessive use of internet cloud has received much of the attention. With the help of cloud data can be easily stored on cloud and can be accessed on demand. There are issues concerning the integrity of the data which is stored on the cloud. There are many reasons for the lack of integrity like error may occur due to human errors, hardware failures , malicious users and many more. Recently some research considers the problem of secure and efficient public data integrity auditing for shared dynamic data. As lot of information is shared on the cloud it is difficult to manage this data as well as maintain its privacy. Now days we face lot of security problem in sharing dynamic data among the group users. Thus to make the sharing more secure we include the vector commitment, group signature, and asymmetric group key agreement scheme. In this we clearly present the sharing of data between the multiple group user...
Research Interests:
Research Interests:
Hemophagocytic lymphohistiocytosis (HLH) is a rare immunopathological syndrome, which can be fatal if not diagnosed early. It is characterized by excessive immune activation and can be observed in all age groups depending on the causes of... more
Hemophagocytic lymphohistiocytosis (HLH) is a rare immunopathological syndrome, which can be fatal if not diagnosed early. It is characterized by excessive immune activation and can be observed in all age groups depending on the causes of HLH. Here, we describe a case of cytomegalovirus-induced HLH in an immunocompromised host which was diagnosed in the setting of high clinical suspicion and insufficient diagnostic information.
Research Interests:
Research Interests:
Research Interests:
Research Interests:
renal disease from ITG in patients with preserved renal function or early renal dysfunction.2 Our patient with ITG had 2 episodes of dialysis-requiring AKI and fortunately responded to rituximab therapy in both instances. The second... more
renal disease from ITG in patients with preserved renal function or early renal dysfunction.2 Our patient with ITG had 2 episodes of dialysis-requiring AKI and fortunately responded to rituximab therapy in both instances. The second episode was not associated with as dramatic of a renal improvement as the first episode, likely due to chronicity of the renal disease. In summary, rituximabmay have a role in the treatment of ITG, and this case suggests that it may be effective in treating recurrent disease as well. A role for rituximab is plausible given its anti–B-cell action, but further studies are needed to better define its potential role in treating ITG.
Research Interests:
In this case, dopaminergic and 5-HT2 receptor blockade may have played a role in producing peripheral edema. Thus, the possible progression of peripheral edema should be considered in patients receiving clothiapine. Selecting another... more
In this case, dopaminergic and 5-HT2 receptor blockade may have played a role in producing peripheral edema. Thus, the possible progression of peripheral edema should be considered in patients receiving clothiapine. Selecting another antipsychotic agent with different pharmacodynamics may suspend the edematous reaction. Future studies should clarify the dose-dependent effects of clothiapine-associated edema and differentiate potential pathogenic roles of the varying forms of clothiapine.
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
renal disease from ITG in patients with preserved renal function or early renal dysfunction.2 Our patient with ITG had 2 episodes of dialysis-requiring AKI and fortunately responded to rituximab therapy in both instances. The second... more
renal disease from ITG in patients with preserved renal function or early renal dysfunction.2 Our patient with ITG had 2 episodes of dialysis-requiring AKI and fortunately responded to rituximab therapy in both instances. The second episode was not associated with as dramatic of a renal improvement as the first episode, likely due to chronicity of the renal disease. In summary, rituximabmay have a role in the treatment of ITG, and this case suggests that it may be effective in treating recurrent disease as well. A role for rituximab is plausible given its anti–B-cell action, but further studies are needed to better define its potential role in treating ITG.
Research Interests:
In this case, dopaminergic and 5-HT2 receptor blockade may have played a role in producing peripheral edema. Thus, the possible progression of peripheral edema should be considered in patients receiving clothiapine. Selecting another... more
In this case, dopaminergic and 5-HT2 receptor blockade may have played a role in producing peripheral edema. Thus, the possible progression of peripheral edema should be considered in patients receiving clothiapine. Selecting another antipsychotic agent with different pharmacodynamics may suspend the edematous reaction. Future studies should clarify the dose-dependent effects of clothiapine-associated edema and differentiate potential pathogenic roles of the varying forms of clothiapine.
Research Interests:
Research Interests:
harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): a case report. Thorac Cancer 2018;9:745–749. 5. Ciesielski MJ, Fenstermaker RA. Oncogenic epidermal growth factor receptor... more
harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): a case report. Thorac Cancer 2018;9:745–749. 5. Ciesielski MJ, Fenstermaker RA. Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene. 2000;19:810–820. 6. Gallant JN, Sheehan JH, Shaver TM, et al. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov. 2015;5:1155–1163. 7. Baik CS, Wu D, Smith C, et al. Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient harboring epidermal growth factor receptor tandem kinase domain duplication. J Thorac Oncol. 2015;10:e97–99.
Research Interests:
harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): a case report. Thorac Cancer 2018;9:745–749. 5. Ciesielski MJ, Fenstermaker RA. Oncogenic epidermal growth factor receptor... more
harboring a rare EGFR L747P mutation showing intrinsic resistance to both gefitinib and osimertinib (AZD9291): a case report. Thorac Cancer 2018;9:745–749. 5. Ciesielski MJ, Fenstermaker RA. Oncogenic epidermal growth factor receptor mutants with tandem duplication: gene structure and effects on receptor function. Oncogene. 2000;19:810–820. 6. Gallant JN, Sheehan JH, Shaver TM, et al. EGFR kinase domain duplication (EGFR-KDD) is a novel oncogenic driver in lung cancer that is clinically responsive to afatinib. Cancer Discov. 2015;5:1155–1163. 7. Baik CS, Wu D, Smith C, et al. Durable response to tyrosine kinase inhibitor therapy in a lung cancer patient harboring epidermal growth factor receptor tandem kinase domain duplication. J Thorac Oncol. 2015;10:e97–99.
Research Interests:
Background: Amyloidosis is the extracellular tissue deposition of small molecular subunits of proteins as fibrils. AL Amyloidosis is a complication of underlying plasma cell dyscrasia with an associated monoclonal paraprotein. It can... more
Background: Amyloidosis is the extracellular tissue deposition of small molecular subunits of proteins as fibrils. AL Amyloidosis is a complication of underlying plasma cell dyscrasia with an associated monoclonal paraprotein. It can occur in association with multiple myeloma (MM), Waldenstrom macroglobulinemia (WM) or non-Hodgkin lymphoma. While isolated organ involvement can be seen, many patients (pts) have multiorgan involvement. Our aim was to explore the trend of amyloidosis associated with plasma cell dyscrasia, treatment and outcome at our institution. Methods: After IRB approval, we reviewed medical records of adult pts ≥ 18 years with a histological diagnosis of amyloid and had evidence of monoclonal gammopathy, between January 1st, 2010 and June 30th, 2019. We reviewed age at diagnosis, gender, work up for paraproteinemia, site of biopsy, technique used for identification of amyloid, imaging studies, treatment and outcome. Results: We found a total of 33 pts with biopsy p...
Research Interests:
Introduction: Amyloidosis is a disease characterized by deposition of congophilic amyloid fibrils in the extracellular matrix of tissues and organs. Although pulmonary involvement in amyloidosis is common, it is rarely symptomatic. The... more
Introduction: Amyloidosis is a disease characterized by deposition of congophilic amyloid fibrils in the extracellular matrix of tissues and organs. Although pulmonary involvement in amyloidosis is common, it is rarely symptomatic. The clinical course is considered indolent or benign, however literature available on biology and history of this disease is limited. Sub-typing of pulmonary amyloidosis has been historically difficult. Pulmonary amyloidosis can be a part of an underlying plasma cell dyscrasia or related to an underlying inflammatory systemic disease. Our aim was to identify the further workup done after a biopsy proven diagnosis of pulmonary amyloidosis and the relation to monoclonal gammopathy. We also investigated the frequency of utilization of mass spectrometry for amyloid typing at our institution. Methods: We reviewed medical records of adult patients ≥ 18 years with localized pulmonary amyloidosis from January 1st 2010 to June 30th 2019. The word "amyloidosis...
Research Interests:
Research Interests:
Research Interests:
Research Interests:
Research Interests:
1. Chourdakis E, Koniari I, Hahalis G, et al. Endocarditis after transcatheter aortic valve implantation: a current assessment. J Geriatr Cardiol. 2018;15:61–65. 2. O’Sullivan CJ, Stortecky S, Bütikofer A, et al. Impact of mitral... more
1. Chourdakis E, Koniari I, Hahalis G, et al. Endocarditis after transcatheter aortic valve implantation: a current assessment. J Geriatr Cardiol. 2018;15:61–65. 2. O’Sullivan CJ, Stortecky S, Bütikofer A, et al. Impact of mitral regurgitation on clinical outcomes of patients with low-ejection fraction, low-gradient severe aortic stenosis undergoing transcatheter aortic valve implantation. Circ Cardiovasc Interv. 2015;8:e001895. 3. Mangner N, Leontyev S, Woitek FJ, et al. Cardiac surgery compared with antibiotics only in patients developing infective endocarditis after transcatheter aortic valve replacement. J Am Heart Assoc. 2018;7:e010027. 4. Cahill TJ, Baddour LM, Habib G, et al. Challenges in infective endocarditis. J Am Coll Cardiol. 2017;69:325–344. 5. Schäfers MT, Abramson MA, Li J, et al. Clinical information determines the impact of transesophageal echocardiography on the diagnosis of infective endocarditis by the duke criteria. Am Heart J. 2000;139:945–951. 6. Nagpal A, Sohail MR, Steckelberg JM. Prosthetic valve endocarditis: state of the heart. Clin Invest. 2012;2:803–817. 7. Habib G. Infective endocarditis after transcatheter aortic valve replacement: the worst that can happen. J Am Heart Assoc. 2018;7:e010287.